European Companies Search Engine
EU funding (€504,000): New Selenium-based Targeted Nanocapsules to treat Breast Cancer Hor31 Oct 2017 EU Research and Innovation programme "Horizon"
Overview
Text
New Selenium-based Targeted Nanocapsules to treat Breast Cancer
The European Chronic Diseases Alliance has defined cancer as one of the major non-communicable diseases, accounting for 13% of the deaths worldwide, resulting in 8.2 million deaths annually. In the NEOSETAC project, breast cancer will be the focus of study being the most common cancers in women. It comprises of 10.4% of all the cancer incidences among women, causing 411 093 deaths per year overall the world. In Europe, there is more than twice of the amount of new breast cancer cases annually than new cases of cancer in any other place. The complexity of breast cancer makes it a big challenge for successful treatment. The NEOSETAC project will demonstrate the anti-cancer therapeutic potential of a novel Seleniumbased therapy for the management of breast cancer. The clinical application of Selenium (Se) compounds for cancer treatment is until now limited in chemoprevention as dietary supplement. In this proposal, we aim to improve the therapeutic window, pharmacokinetic properties and targeting drug delivery via nanoparticles (NPs). By loading Se into biodegradable NPs, drug release is controlled within the narrow therapeutic window of Se. At the same time the uptake and activation of Se compounds at desired location (tumor lesions and metastasis) is achieved. We also propose to functionalize NPs by cancer cell / cancer stem cell targeting ligands to further improve the therapeutic efficacy and prevent cancer recurrence after chemotherapy. These advantages will lead to an enhanced anticancer activity and reduced systemic toxicity. Moreover, targeting via NPs will improve the pharmacokinetic properties and increase the relatively short half-life (~18 hours) of Se.
Funded Companies:
| Company name | Funding amount |
| AB BCN SL | €22,500 |
| Acib GmbH | €27,000 |
| Adsi-Austrian Drug Screening Institute GmbH | €27,000 |
| Clinisciences SL | €22,500 |
| Karolinska Institutet | €40,635 |
| Qualizyme Diagnostics GmbH & Co. KG | €0.00 |
| Redinn - Srl | €67,500 |
| Region Stockholm | €94,365 |
| Universitat Autonoma de Barcelona | €202,500 |
Source: https://cordis.europa.eu/project/id/778325
The filing refers to a past date, and does not necessarily reflect the current state.
